Jardiance International Purchase Legalities: What Women Need to Know Before Buying Empagliflozin Abroad

What Jardiance Actually Costs in the US, and Why Women Are Looking Abroad

The price gap is real. Jardiance (empagliflozin) carries a list price of approximately $670 per month for the 10 mg or 25 mg dose in the United States, making it one of the more expensive oral cardiometabolic drugs on the market. Women without comprehensive drug coverage, those on high-deductible plans, or those using Jardiance off-label for conditions like polycystic ovary syndrome (PCOS) often find insurance won't cover it at all.

That price disparity sends a lot of women searching for the same drug in Canada, Mexico, or through online pharmacies claiming to ship from the UK or Australia. Before you click "add to cart," you need to understand what the law actually says, what the FDA actually does, and what safer alternatives exist for reducing your out-of-pocket costs.

How Empagliflozin Is Priced Outside the US

Government price negotiations in countries like Canada, the UK, and Australia mean empagliflozin costs a fraction of its US price. In Canada, a 30-day supply of Jardiance 10 mg typically runs between CAD $80 and $130 through a licensed provincial pharmacy. The NHS in England covers empagliflozin for type 2 diabetes under technology appraisal TA336, with minimal out-of-pocket costs to patients. Australian patients pay AU $30.60 or less under the Pharmaceutical Benefits Scheme.

Women living near the Canadian or Mexican border, in particular, have long sought prescription drugs across the border for cost reasons. This is not a new phenomenon, and the legal framework around it has not meaningfully changed in decades, which is itself part of the problem.

The Three-Drug Pricing Tiers Women Should Know

| Source | Approximate Monthly Cost | Legal Status for US Resident | |---|---|---| | US retail, no insurance | $650-$700 | Fully legal | | US retail, manufacturer card | $10-$35 | Fully legal | | Canadian licensed pharmacy | $80-$150 | Gray area (see below) | | Mexican pharmacy in person | $60-$120 | Gray area (see below) | | Unlicensed online "pharmacy" | Variable | Illegal and unsafe |

The FDA's Personal Importation Policy: What It Actually Says

The FDA does not permit personal importation of foreign-purchased prescription drugs as a general rule. FDA guidance on personal importation states that prescription drugs manufactured abroad for foreign markets have not been evaluated by FDA and technically cannot be legally imported for personal use. This applies to Jardiance purchased from a Canadian or Mexican pharmacy, even if the drug is chemically identical.

Full stop, that is the legal baseline.

When the FDA Looks the Other Way

The agency has long exercised enforcement discretion for personal-use quantities. A 2024 updated FDA import alert clarifies that FDA officers at ports of entry and mail facilities may release a personal importation of a prescription drug if:

• The quantity is no more than a 90-day personal supply
• The drug does not appear to pose an unreasonable health risk
• The drug is for a serious condition for which no comparable US treatment is available, or the cost barrier is documented
• The individual has a valid prescription from a licensed US physician

Type 2 diabetes qualifies as a serious condition. In practice, a woman ordering a 90-day supply of empagliflozin from a licensed Canadian pharmacy with her US prescription in hand is very unlikely to face enforcement action. The US Customs and Border Protection data for 2023 showed zero reported civil or criminal prosecutions for personal-use drug importation from Canada by individual consumers, though CBP does not publish granular drug-by-drug statistics.

What "Licensed" Actually Means for Canadian Pharmacies

This distinction matters enormously. A legitimate Canadian pharmacy:

• Operates under a provincial pharmacy license (e.g., College of Pharmacists of British Columbia or Ontario College of Pharmacists)
• Requires a valid prescription from a licensed physician
• Dispenses only Health Canada-approved products
• Has a registered pharmacist available by phone or secure message
• Does not sell controlled substances internationally

The Canadian International Pharmacy Association (CIPA) maintains a verified member list. Cross-referencing any pharmacy you consider against that list is the single most important safety step you can take. Sites that offer Jardiance without a prescription, ship from multiple unclear countries, or offer prices below $50/month for brand-name empagliflozin are almost certainly dispensing counterfeit or substandard product.

Mexico: In-Person vs. Mail Order

Crossing into Mexico and purchasing Jardiance at a farmacia is a different legal calculation than ordering online. Many US residents in border states do this regularly. You may bring back a personal supply, but US Customs officers have discretion to confiscate any prescription drug not approved by the FDA, even if you have a US prescription. For a chronic medication like empagliflozin, the reliability issue, what happens when you can't cross the border, argues against making this your primary supply chain.

How to Get Jardiance Cheaper Without Leaving the US

Several legitimate, fully legal options exist that many women have not explored. These deserve more attention than international sourcing for most patients.

The Lilly/Boehringer Ingelboth Savings Card

Eli Lilly and Boehringer Ingelheim co-market Jardiance and offer a savings card program for commercially insured patients. Eligible women pay as little as $10 per month, with a cap on the annual benefit. The key limitation: this card cannot be used with Medicare, Medicaid, or any federal health insurance program. If you are commercially insured and paying full price, check this program first.

Lilly Cares Foundation (Patient Assistance)

For uninsured or underinsured patients, the Lilly Cares Foundation provides Jardiance at no cost to qualifying patients. Income thresholds apply and are updated annually. In 2025, a single person earning up to 400% of the federal poverty level may qualify. Applications are submitted by your prescriber or directly online.

State-Level Drug Importation Programs

As of 2026, three US states have active FDA-approved wholesale drug importation programs from Canada: Florida, Colorado, and Tennessee. Florida's program, approved under Section 804 of the Federal Food, Drug, and Cosmetic Act, was the first to receive FDA authorization and began limited drug distribution in 2024. Jardiance is not yet on the approved formulary for these state programs, but the list is expanding. Women in these states should check their state pharmacy board websites annually for updates.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) does not yet carry brand-name Jardiance, but it does carry generic empagliflozin. The FDA approved the first generic empagliflozin in early 2024, and generic pricing through discount platforms has dropped the monthly cost to $40-$80 at some pharmacies. Ask your prescriber specifically whether substituting generic empagliflozin is appropriate for your situation.

GoodRx and Pharmacy Discount Programs

GoodRx prices for generic empagliflozin at large pharmacy chains (Costco, Walmart, Kroger) have ranged from $35 to $90/month depending on your zip code. These prices fluctuate weekly. The GoodRx discount cannot be combined with insurance in most states, so compare your insurance copay against the GoodRx cash price before choosing.

Can You Use HSA or FSA Dollars?

Yes. Empagliflozin with a valid prescription is an eligible HSA/FSA expense under IRS Publication 502. This applies to both brand-name Jardiance and generic empagliflozin. If you are in the 22% or 24% federal tax bracket, paying through an HSA effectively reduces your drug cost by that percentage. For a woman paying $80/month for generic empagliflozin, the after-tax cost through an HSA drops to approximately $61-$62/month.

Sex-Specific Physiology: How Empagliflozin Works Differently in Women

Empagliflozin works by blocking the SGLT2 transporter in the kidney, causing the kidneys to excrete glucose in urine regardless of insulin status. The EMPA-REG OUTCOME trial, published in the New England Journal of Medicine in 2015, enrolled 7,020 patients with T2D and established cardiovascular risk, showing a 38% reduction in cardiovascular death compared with placebo. Women made up 28.5% of that trial population, which is a known limitation.

Genital Mycotic Infections: A Real and Underreported Risk in Women

The most common sex-specific adverse effect of empagliflozin is genital mycotic infection (vulvovaginal candidiasis). In the EMPA-REG OUTCOME trial, the rate of genital mycotic infections was approximately 10% in women taking empagliflozin vs. 2.6% in women taking placebo. This is nearly four times higher in women than in men on the same drug.

If you have a history of recurrent yeast infections, this risk is relevant to your prescribing conversation. Good perineal hygiene, prompt treatment of early symptoms, and possibly prophylactic antifungal use during the first three months of therapy are options your clinician can discuss with you.

Urinary Tract Infections

Women already have a higher baseline UTI risk than men. Empagliflozin increases glycosuria, which can theoretically increase UTI risk, though the EMPA-REG data showed only a modest increase. Women with recurrent UTIs or structural urinary tract abnormalities should discuss this risk specifically with their provider before starting.

Bone Density Considerations

SGLT2 inhibitors as a class have been associated with increased fracture risk in some trials, though a 2022 meta-analysis in JAMA Network Open found no statistically significant increase in fracture risk with empagliflozin specifically. Women in perimenopause or postmenopause already face accelerating bone loss; this is worth tracking with your DEXA scan schedule.

Empagliflozin Across Life Stages

Reproductive Years: PCOS and Insulin Resistance

Polycystic ovary syndrome affects 8-13% of women of reproductive age and is strongly linked to insulin resistance. Empagliflozin is not FDA-approved for PCOS, but off-label use is growing based on its mechanism. A 2023 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism found that empagliflozin reduced fasting insulin, androgen levels, and BMI in women with PCOS over 12 weeks compared with placebo. This is an active area of research. Women with PCOS who are also trying to conceive should discuss timing carefully with their reproductive endocrinologist, given the pregnancy contraindication below.

Perimenopause: Metabolic Shifts and Cardiovascular Risk

The menopausal transition is associated with increased visceral adiposity, worsening insulin resistance, and a rising cardiovascular risk profile even in women without prior diabetes. The Menopause Society 2023 position statement notes that cardiovascular risk management in the perimenopausal decade is a clinical priority. For women in perimenopause who have T2D or prediabetes with cardiac risk factors, empagliflozin's cardiovascular and renal protective data are directly relevant.

Postmenopause: Heart Failure and Kidney Protection

The EMPEROR-Reduced trial and EMPEROR-Preserved trial demonstrated heart failure benefits of empagliflozin regardless of diabetes status. Postmenopausal women with heart failure with preserved ejection fraction (HFpEF), a condition that disproportionately affects women, showed meaningful reductions in cardiovascular death and hospitalization. This expanded the FDA indication for Jardiance in 2022 beyond T2D to include chronic heart failure and chronic kidney disease.

A practical life-stage framework for empagliflozin in women:

| Life Stage | Primary Use Case | Key Consideration | |---|---|---| | Reproductive years, T2D/PCOS | Glycemic and androgen control | Contraception required; stop if pregnant | | Trying to conceive | Generally avoid | Insufficient safety data; transition to safer agent | | Pregnancy | Contraindicated 2nd/3rd trimester | Do not use; category not yet fully characterized | | Postpartum/lactation | Avoid | Present in animal milk; human data absent | | Perimenopause | Cardiometabolic management | Monitor bone density; watch for UTI pattern change | | Postmenopause | Heart failure, CKD, T2D | Full indication; renal dosing adjustments may apply |

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Pregnancy: Contraindicated in the Second and Third Trimesters

Empagliflozin is contraindicated during the second and third trimesters of pregnancy. The FDA prescribing information warns that SGLT2 inhibitors may adversely affect renal development in the fetus during the second and third trimesters, a period when fetal kidneys begin processing amniotic fluid. The specific risks include oligohydramnios, reduced fetal renal function, and potential neonatal renal dysfunction.

First-trimester safety data in humans is limited. Animal studies at doses relevant to human exposure showed no clear teratogenicity, but the absence of human teratogenicity data is not reassurance. ACOG consistently advises against the use of oral antidiabetic drugs without established human pregnancy safety data when safer alternatives like insulin exist.

The clinical recommendation is clear: stop empagliflozin before conception if possible, and transition to insulin under obstetric supervision.

What to Do If You Become Pregnant While Taking Jardiance

If you discover you are pregnant while taking empagliflozin, stop the medication immediately and contact your obstetric provider the same day. Do not wait for your next scheduled appointment. Your provider will likely transition you to insulin for glycemic management and arrange early fetal renal ultrasound monitoring depending on gestational age at exposure.

Lactation

No human data exist on empagliflozin transfer into breast milk. Animal studies show the drug is present in rat milk. Because of the potential for serious adverse effects on the nursing infant's renal function and glucose metabolism, the FDA label advises against use during breastfeeding. This is a case where the evidence gap is real: no lactation pharmacokinetic studies in humans have been published as of early 2026.

Contraception Requirements

Empagliflozin is not classified as a teratogen in the way that medications like valproate or isotretinoin are, meaning there is no formal mandatory contraception program. Regardless, women of reproductive age who are not planning pregnancy should use reliable contraception while taking empagliflozin given the second and third trimester contraindication. Discuss contraceptive options with your prescriber, particularly if you have PCOS, where hormonal contraception choices interact with insulin resistance management.

Who This Is Right For, and Who Should Pause

Women Who May Benefit Most

• Women with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, based on the EMPA-REG OUTCOME mortality data
• Postmenopausal women with heart failure with preserved ejection fraction
• Women with chronic kidney disease (eGFR >20 mL/min/1.73m²) and proteinuria, based on the EMPA-KIDNEY trial
• Women with PCOS and insulin resistance who have not responded to metformin alone and are not trying to conceive (off-label, discuss with your provider)

Women Who Should Not Take Empagliflozin or Should Use It with Caution

• Currently pregnant or planning conception imminently
• Breastfeeding
• History of recurrent diabetic ketoacidosis; SGLT2 inhibitors carry a risk of euglycemic DKA, including in type 1 diabetes (not FDA-approved for T1D)
• Severe recurrent genital mycotic infections with no clear treatment plan
• eGFR <20 mL/min/1.73m² (inadequate renal function for glycemic efficacy; heart failure indication may still apply with specialist oversight)
• Active urinary tract infection at time of initiation

Practical Steps Before You Order Anything Online

1. Pull your current insurance formulary. Log into your insurer's portal and search for empagliflozin. Check both Tier 3 and Tier 4; some plans place it on specialty tier.
2. Ask your prescriber specifically about generic empagliflozin. The bioequivalence standard means the same pharmacology at a fraction of the cost.
3. Apply for the Lilly/Boehringer savings card or Lilly Cares program before assuming you have no options.
4. If you still need lower cost access: contact only CIPA-verified Canadian pharmacies, use your US prescription, and order no more than a 90-day supply.
5. Never order from a site that does not require a valid prescription. Counterfeit SGLT2 inhibitors have been identified by FDA in seized shipments. A drug that looks like Jardiance but contains a different compound or incorrect dose carries direct patient harm risk.